Israeli medical device company Butterfly Medical today announced that its novel medical device for non-surgical, office-based treatment of Benign Prostate Hyperplasia (BPH), has obtained European CE Mark approval.
BPH or enlarged prostate affects about 105 million men globally ?- more than 4 out 10 men over the age of 50 . Its symptoms often include problems urinating, interrupted sleep as well as sexual dysfunction that can cause loss of productivity, depression and decreased quality of life. Medication is often the first-line therapy, but relief can be inadequate and temporary, with patients needing invasive surgical procedures.
Butterfly Medical’s solution expands the treatment options for BPH sufferers, by providing a simple, fast and minimally invasive, in-office procedure, as an alternative to first-line drug treatment or surgery.
Butterfly Medical’s innovative device is designed to dilate the prostatic urethra without surgical incision or prostate tissue removal. The Butterfly device’s unique design secures tightly to the prostate tissue, preventing any chance of migration, and moves the obstructing lobes of the prostate out of the way to improve urine flow.